Drug Trial Radar · NCT06708455
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Mar 1, 2027
Primary completion
Mar 1, 2029
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Rapa Therapeutics LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.
Conditions
- Malignant Melanoma With Metastasis
- Malignant Melanoma
- Malignant Melanoma Stage IIIc
- Malignant Melanoma Stage IV
Interventions
RAPA-201 Rapamycin Resistant T CellsBiological
Autologous Rapamycin-Resistant Th1/Tc1 Cells
Chemotherapy Prior to RAPA-201 TherapyDrug
Carboplatin + Paclitaxel Regimen (CP Regimen)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of RAPA-201 Cell TherapyTime frame: 18 months (6 mo. of treatment; 12 mo of clinical follow-up)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hackensack University Medical Center
Hackensack, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.